In an interview with CURE®, Dr. Eric Okay. Singhi shared his insights into the first benefits of using the subcutaneous formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) in contrast with the intravenous (IV) model in eligible sufferers. He additionally went on so as to add his ideas on how this may occasionally affect therapy adherence and high quality of life for sufferers receiving immunotherapy.
Notably, this interview got here following the Dec. 27, 2024, Meals and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo for sufferers with strong tumors.
Glossary
Intravenous (IV): when a needle is inserted right into a vein to manage fluids or medicines immediately into the bloodstream.
Subcutaneous: beneath the pores and skin.
Singhi presently serves as an assistant professor in each the Division of Common Oncology and the Division of Thoracic/Head and Neck Medical Oncology, Division of Most cancers Drugs, at The College of Texas MD Anderson Most cancers Heart, in Houston, Texas. To learn our full interview with the skilled, click on right here.
Transcript:
From the affected person perspective, the first benefits of getting this under-the-skin, subcutaneous formulation of Opdivo can embody a shorter administration time. The subcutaneous injection may be accomplished in simply three to 5 minutes in contrast with the 30-minute infusion time that is required for the IV model of Opdivo. This does not appear to be quite a bit, however when you consider the affect of time toxicity that is related to most cancers remedies, — which incorporates visits to the physician, lab checks, scans, infusion occasions and even going to the pharmacy to choose up your medicines — simply saving 25 minutes or extra may imply quite a bit for a affected person and their household, permitting them to keep up a extra regular routine. That is positively one thing to consider.
It is also extra handy. Some sufferers have problem with venous entry, getting an IV put in, having the ability to get the IV formulation of a drugs. This is a chance to have an under-the-skin immunotherapy model that could possibly be far more handy for these sufferers. It additionally gives a extra patient-centric expertise. The choice for under-the-skin, subcutaneous injections may scale back the frequency of hospital visits. It may doubtlessly permit for remedies to be nearer to a affected person’s residence.
The subcutaneous formulation may enhance therapy adherence by making the remedy extra handy and fewer disruptive to sufferers’ lives. With a faster administration time and the potential of receiving the therapy nearer to residence, sufferers might discover it simpler to need to proceed their therapy as prescribed, decreasing the probability of missed doses. This comfort also can enhance the general high quality of life by minimizing the time that sufferers and their family members must spend in medical amenities.
Transcript was edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
